alphav Vitronectin receptors in vascular-mediated disorders.

Abstract

Various integrin antagonist candidates including antibodies, cyclic peptides, peptidomimetics, and non-peptides have been clinically evaluated and shown to successfully modulate certain disease processes. This review will focus on the key role of the alphav integrin (alphavbeta3 and alphavbeta5) in vascular disorders such as restenosis and angiogenesis-mediated disorders.

Cite this paper

@article{Mousa2003alphavVR, title={alphav Vitronectin receptors in vascular-mediated disorders.}, author={Shaker A. Mousa}, journal={Medicinal research reviews}, year={2003}, volume={23 2}, pages={190-9} }